by goldfishadmin | May 22, 2012 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, was recently profiled on the front page of BioWorld Today. A featured article on Orphagen Pharmaceuticals, titled “Orphagen Seeks Ligands for Orphan Nuclear Receptors”, highlighted the...
by goldfishadmin | Feb 7, 2012 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that the National Institutes of Health has awarded the Company $220,839 in funding through the Small Business Innovative Research (SBIR) program. The Phase I grant is designed...
by goldfishadmin | Oct 29, 2010 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that a total of $622,971 in grants was awarded under the Qualifying Therapeutic Discovery Project (QTDP) program provided for in the Health Care and Education Reconciliation...
by goldfishadmin | Aug 10, 2010 | News
Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs for the treatment of adrenocortical and prostate cancer. The objective of the...
by goldfishadmin | Feb 1, 2010 | News
Orphagen Pharmaceuticals announced today that it has been awarded a two year federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian rhythm sleep disorders and more serious psychiatric illnesses, such as anxiety,...
